Outlook
Mass spectrometry has undergone major advances in recent years and is reshaping the landscape in which drug companies perform their metabolite identification studies. Pharmaceutical organizations have come to expect instruments that require minimal user intervention, offer high-throughput analysis and provide high-quality data. With the bottleneck in the process shifting to data processing, data-reduction techniques must continue to evolve to meet this challenge.